Login to Your Account

Pharma: Clinic Roundup

Thursday, August 1, 2013
• Boehringer Ingelheim Pharmaceuticals GmbH, of Ingelheim, Germany, and Eli Lilly and Co., of Indianapolis, jointly announced enrollment of the first patient into a cardiovascular (CV) and renal outcomes trial for the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin (Tradjenta) tablets.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription